398 related articles for article (PubMed ID: 19491669)
21. Role of stem cell transplantation.
Harousseau JL
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
[TBL] [Abstract][Full Text] [Related]
22. Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma.
Moreau P
Expert Rev Anticancer Ther; 2009 Jul; 9(7):885-90. PubMed ID: 19589027
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the mangement of multiple myeloma.
Kumar L; Vikram P; Kochupillai V
Natl Med J India; 2006; 19(2):80-9. PubMed ID: 16756196
[TBL] [Abstract][Full Text] [Related]
24. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
25. Intensive therapy in multiple myeloma.
Harousseau JL
Pathol Biol (Paris); 1999 Feb; 47(2):203-9. PubMed ID: 10192890
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?
Aljitawi OS; McGuirk JP
J Comp Eff Res; 2012 Jan; 1(1):57-70. PubMed ID: 24237297
[TBL] [Abstract][Full Text] [Related]
27. Management of multiple myeloma: the changing landscape.
Reece DE
Blood Rev; 2007 Nov; 21(6):301-14. PubMed ID: 17761373
[TBL] [Abstract][Full Text] [Related]
28. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
[TBL] [Abstract][Full Text] [Related]
29. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
30. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
van Rhee F
Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985
[No Abstract] [Full Text] [Related]
31. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
Lenhoff S; Hjorth M; Westin J; Brinch L; Bäckström B; Carlson K; Christiansen I; Dahl IM; Gimsing P; Hammerström J; Johnsen HE; Juliusson G; Linder O; Mellqvist UH; Nesthus I; Nielsen JL; Tangen JM; Turesson I;
Br J Haematol; 2006 May; 133(4):389-96. PubMed ID: 16643445
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
33. [Current therapy concepts in patients with multiple myeloma].
Heyll A; Schneider P; Bauser U; Kobbe G; Hünerlitürkoglu A; Aul C; Haas R
Dtsch Med Wochenschr; 2000 Oct; 125(40):1201-9. PubMed ID: 11075253
[No Abstract] [Full Text] [Related]
34. [Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma].
Ohashi K
Gan To Kagaku Ryoho; 2008 Jun; 35(6):1029-32. PubMed ID: 18633240
[TBL] [Abstract][Full Text] [Related]
35. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic.
Gibson J; Ho PJ; Joshua D
Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295
[TBL] [Abstract][Full Text] [Related]
36. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
Moreau P; Giralt SA
Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
[TBL] [Abstract][Full Text] [Related]
37. Treatment of relapsed/refractory multiple myeloma.
Kastritis E; Palumbo A; Dimopoulos MA
Semin Hematol; 2009 Apr; 46(2):143-57. PubMed ID: 19389498
[TBL] [Abstract][Full Text] [Related]
38. Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB
J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138
[TBL] [Abstract][Full Text] [Related]
39. Individualizing treatment of patients with myeloma in the era of novel agents.
San-Miguel J; Harousseau JL; Joshua D; Anderson KC
J Clin Oncol; 2008 Jun; 26(16):2761-6. PubMed ID: 18427148
[TBL] [Abstract][Full Text] [Related]
40. Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant.
Niesvizky R; Coleman M; Mark T
Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):14-21. PubMed ID: 20518366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
